Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE) : a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial

被引:0
|
作者
Allen, Jeffrey A. [1 ]
Lin, Jie [2 ]
Basta, Ivana [3 ]
Dysgaard, Tina [4 ]
Eggers, Christian [5 ]
Guptill, Jeffrey [6 ,7 ]
Gwathmey, Kelly G. [8 ]
Hewamadduma, Channa [9 ,10 ]
Hofman, Erik [6 ]
Hussain, Yessar M. [11 ]
Kuwabara, Satoshi [12 ]
Le Masson, Gwendal [13 ]
Leypoldt, Frank [14 ,15 ]
Chang, Ting [16 ]
Lipowska, Marta [17 ,18 ]
Lowe, Murray [6 ]
Lauria, Giuseppe [19 ]
Querol, Luis [20 ,21 ]
Simu, Mihaela-Adriana [22 ]
Suresh, Niraja [23 ]
Tse, Anissa [6 ]
Ulrichts, Peter [6 ]
Van Hoorick, Benjamin [6 ]
Yamasaki, Ryo [24 ,25 ]
Lewis, Richard A. [26 ]
van Doorn, Pieter A. [27 ]
机构
[1] Univ Minnesota, Dept Neurol, Minneapolis, MN 55455 USA
[2] Fudan Univ, Huashan Hosp, Dept Neurol, Shanghai, Peoples R China
[3] Univ Belgrade, Univ Clin Ctr Serbia, Fac Med, Neurol Clin, Belgrade, Serbia
[4] Univ Copenhagen, Dept Neurol, Copenhagen, Denmark
[5] Johannes Kepler Univ Linz, Kepler Univ Hosp, Dept Neurol, Linz, Austria
[6] Argenx, Ghent, Belgium
[7] Duke Univ, Sch Med, Durham, NC USA
[8] Virginia Commonwealth Univ, Dept Neurol, Richmond, VA USA
[9] Univ Sheffield, Sheffield Inst Translat Neurosci SITRAN, Sheffield, England
[10] Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, England
[11] Austin Neuromuscular Ctr, Austin, TX USA
[12] Chiba Univ, Grad Sch Med, Dept Neurol, Chiba, Japan
[13] Univ Hosp Bordeaux, AOC Natl Reference Ctr Neuromuscular Disorders, ALS Ctr, Dept Neurol,CHU Bordeaux,NerveMuscle Unit, Bordeaux, France
[14] Christian Albrecht Univ Kiel, Inst Clin Chem, Dept Neurol, Kiel, Germany
[15] Univ Med Ctr Schleswig Holstein, Kiel, Germany
[16] Fourth Mil Med Univ, Tangdu Hosp, Dept Neurol, Xian, Peoples R China
[17] Med Univ Warsaw, Dept Neurol, Warsaw, Poland
[18] European Reference Network Rare Neuromuscular Dis, Paris, France
[19] IRCCS Fdn Ist Neurol Carlo Besta, Milan, Italy
[20] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Dept Neurol, Neuromuscular Dis Unit, Barcelona, Spain
[21] Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain
[22] Victor Babes Univ Med & Pharm, Dept Neurol, Timisoara, Romania
[23] Univ S Florida, Dept Neurol, Tampa, FL USA
[24] Kyushu Univ Hosp, Dept Neurol, Fukuoka, Japan
[25] Kyushu Univ, Neurol Inst, Grad Sch Med Sci, Dept Neurol, Fukuoka, Japan
[26] Cedars Sinai Med Ctr, Dept Neurol, Los Angeles, CA USA
[27] Erasmus MC, Univ Med Ctr, Dept Neurol, Rotterdam, Netherlands
来源
LANCET NEUROLOGY | 2024年 / 23卷 / 10期
关键词
NERVE SOCIETY GUIDELINE; MANAGEMENT; CIDP; IVIG;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an autoimmune disease of the peripheral nervous system that can lead to severe disability from muscle weakness and sensory disturbances. Around a third of patients do not respond to currently available treatments, and many patients with a partial response have residual neurological impairment, highlighting the need for effective alternatives. Efgartigimod alfa, a human IgG1 antibody Fc fragment, has demonstrated efficacy and safety in patients with generalised myasthenia gravis. We evaluated the safety, tolerability, and efficacy of subcutaneous efgartigimod PH20 in adults with CIDP.<br /> Methods ADHERE, a multistage, double-blind, placebo-controlled trial, enrolled participants with CIDP from 146 clinical sites from Asia-Pacific, Europe, and North America. Participants with evidence of clinically meaningful deterioration entered an open-label phase of weekly 1000 mg subcutaneous efgartigimod PH20 for no longer than 12 weeks (stage A). Those with confirmed evidence of clinical improvement (ECI; treatment responders) entered a randomised-withdrawal phase of 1000 mg subcutaneous efgartigimod PH20 weekly treatment versus placebo for a maximum of 48 weeks (stage B). Participants were randomised (1:1) through interactive response technology and stratified by their adjusted Inflammatory Neuropathy Cause and Treatment (aINCAT) score change during stage A and their most recent CIDP medication within 6 months before screening. Investigators, the clinical research organisation, and participants were masked to the treatment. The primary endpoint in stage A, evaluated in the stage A safety population, was confirmed ECI (>= 1 points aINCAT decrease, >= 4 points [centile metric] Inflammatory Raschbuilt Overall Disability Scale increase, or >= 8 kPa grip strength increase after four injections and two consecutive visits). The primary endpoint in stage B, evaluated in the modified intention-to-treat population, was the risk of relapse (time to first aINCAT increase of >= 1 points). ADHERE is registered with ClinicalTrials.gov (NCT04281472) and EudraCT (2019-003076-39) and is completed.<br /> Findings Between April 15, 2020, and May 11, 2023, 629 participants were screened; 322 (114 female, 208 male) entered stage A, of whom 214 (66%, 95% CI 61<middle dot>0-71<middle dot>6) had confirmed ECI. In stage B, 221 participants were randomised (79 female, 142 male; 111 to subcutaneous efgartigimod PH20, 110 to placebo). Subcutaneous efgartigimod PH20 significantly reduced the risk of relapse versus placebo (hazard ratio 0<middle dot>39 [95% CI 0<middle dot>25-0<middle dot>61]; p<0<middle dot>0001). 31 (27<middle dot>9% [19<middle dot>6-36<middle dot>3]) participants given subcutaneous efgartigimod PH20 had a relapse versus 59 (53<middle dot>6% [44<middle dot>3-63<middle dot>0]) given placebo. In stage A, treatment-emergent adverse events (TEAEs) occurred in 204 (63%) participants and serious TEAEs in 21 (7%). In stage B, TEAEs occurred in 71 (64%) participants on subcutaneous efgartigimod PH20 and 62 (56%) participants on placebo, and serious TEAEs in six (5%) on subcutaneous efgartigimod PH20 and six (5%) on placebo. Three deaths occurred: two in stage A (one non-related and one unlikely related to treatment) and one in stage B (placebo group).<br /> Interpretation ADHERE showed the efficacy of subcutaneous efgartigimod PH20 in reducing the risk of relapse versus placebo in people with CIDP who responded to treatment. Further studies are needed to provide data on the longer-term effects of efgartigimod alfa and how it compares with currently available treatment options.
引用
收藏
页码:1013 / 1024
页数:12
相关论文
共 50 条
  • [1] Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial
    Hughes, Richard
    Dalakas, Marinos C.
    Merkies, Ingemar
    Latov, Norman
    Leger, Jean-Marc
    Nobile-Orazio, Eduardo
    Sobue, Gen
    Genge, Angela
    Cornblath, David
    Merschhemke, Martin
    Ervin, Carolyn Marie
    Agoropoulou, Catherine
    Hartung, Hans-Peter
    LANCET NEUROLOGY, 2018, 17 (08): : 689 - 698
  • [2] Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT) : a multicentre, randomised, placebo-controlled, phase 3 trial
    Howard, James F. Jr Jr
    Bril, Vera
    Vu, Tuan
    Karam, Chafic
    Perk, Stojan
    Margania, Temur
    Murai, Hiroyuki
    Bilinska, Malgorzata
    Shakarishvili, Roman
    Smilowski, Marek
    Guglietta, Antonio
    Ulrichts, Peter
    Vangeneugden, Tony
    Utsugisawa, Kimiaki
    Verschuuren, Jan
    Mantegazza, Renato
    LANCET NEUROLOGY, 2021, 20 (07): : 526 - 536
  • [3] Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial
    Misawa, Sonoko
    Sato, Yasunori
    Katayama, Kanako
    Nagashima, Kengo
    Aoyagi, Reiko
    Sekiguchi, Yukari
    Sobue, Gen
    Koike, Haruki
    Yabe, Ichiro
    Sasaki, Hidenao
    Watanabe, Osamu
    Takashima, Hiroshi
    Nishizawa, Masatoyo
    Kawachi, Izumi
    Kusunoki, Susumu
    Mitsui, Yoshiyuki
    Kikuchi, Seiji
    Nakashima, Ichiro
    Ikeda, Shu-ichi
    Kohara, Nobuo
    Kanda, Takashi
    Kira, Jun-ichi
    Hanaoka, Hideki
    Kuwabara, Satoshi
    LANCET NEUROLOGY, 2016, 15 (11): : 1129 - 1137
  • [4] Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial
    van Schaik, Ivo N.
    Bril, Vera
    van Geloven, Nan
    Hartung, Hans-Peter
    Lewis, Richard A.
    Sobue, Gen
    Lawo, John-Philip
    Praus, Michaela
    Mielke, Orell
    Durn, Billie L.
    Cornblath, David R.
    Merkies, Ingemar S. J.
    LANCET NEUROLOGY, 2018, 17 (01): : 35 - 46
  • [5] Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study
    Querol, Luis
    De Seze, Jerome
    Dysgaard, Tina
    Levine, Todd
    Rao, T. Hemanth
    Rivner, Michael
    Hartung, Hans-Peter
    Kiessling, Peter
    Shimizu, Saori
    Marmol, Dominika
    Bozorg, Ali
    Colson, Anny-Odile
    Massow, Ute
    Eftimov, Filip
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2024, 95 (09): : 845 - 854
  • [6] Safety and efficacy of GD-11 in patients with ischaemic stroke: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial
    Zhang, Runhua
    Liu, Gaifen
    Zhao, Xingquan
    Wang, Yilong
    Li, Zixiao
    Chen, Guofang
    Liu, Bo
    Ling, Yun
    Wang, Yongjun
    Li, Shuya
    STROKE AND VASCULAR NEUROLOGY, 2024,
  • [7] EFFICACY AND SAFETY OF JZP-258 IN A PHASE 3 DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMISED-WITHDRAWAL STUDY IN ADULTS WITH NARCOLEPSY WITH CATAPLEXY
    Bogan, R.
    Thorpy, M.
    Dauvilliers, Y.
    Villegas, R. Del Rio
    Foldvary-Schaefer, N.
    Skowronski, R.
    Liu, K.
    Skobieranda, F.
    Sonka, K.
    SLEEP MEDICINE, 2019, 64 : S43 - S43
  • [8] Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
    Gouni-Berthold, Ioanna
    Alexander, Veronica J.
    Yang, Qingqing
    Hurh, Eunju
    Steinhagen-Thiessen, Elisabeth
    Moriarty, Patrick M.
    Hughes, Stephen G.
    Gaudet, Daniel
    Hegele, Robert A.
    O'Dea, Louis St L.
    Stroes, Erik S. G.
    Tsimikas, Sotirios
    Witztum, Joseph L.
    LANCET DIABETES & ENDOCRINOLOGY, 2021, 9 (05): : 264 - 275
  • [9] EFFICACY AND SAFETY OF SUBCUTANEOUS EFGARTIGIMOD PH20 IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY: ADHERE/ADHERE plus TRIAL
    Hussain, Yessar
    Allen, Jeffrey A.
    Le Masson, Gwendal
    Suresh, Niraja
    Hewamadduma, Channa
    Lin, Jie
    Lipowska, Marta
    Lauria, Giuseppe
    Simu, Mihaela-Adriana
    Chang, Ting
    Kuwabara, Satoshi
    Guptill, Jeffrey T.
    Dysgaard, Tina
    Eggers, Christian
    Leypoldt, Frank
    MUSCLE & NERVE, 2024, 70 (03) : 537 - 537
  • [10] Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
    Gordon, Kenneth B.
    Foley, Peter
    Krueger, James G.
    Pinter, Andreas
    Reich, Kristian
    Vender, Ronald
    Vanvoorden, Veerle
    Madden, Cynthia
    White, Katy
    Cioffi, Christopher
    Blauvelt, Andrew
    LANCET, 2021, 397 (10273): : 475 - 486